Currently, GLP-1R agonists used in the treatment of AD models include (Val8)GLP-1, GLP-1(9-36)amide, GLP-1(7-36)amide, CJC-1131, Geniposide, Exendin(5-39), Exendin-4, NLY01 (engineered exendin-4), liraglutide, Lixisenatide, Dulaglutide, Exenatide, GLP-1, dual GLP-1/GIP receptor agonist (DA-JC4, DA-JC1, DA5-CH, DA-CH3), GLP-1/GIP/Gcg receptor triagonist (triagonist, TA), dual GLP-1 and Gcg receptor agonist (oxyntomodulin) (144, 147, 148, 150, 171, 180, 186, 189, 194, 218, 219, 228, 235, 237, 238, 241, 242)
Novo Nordisk may have first-mover advantage in the oral space, with oral Wegovy (obesity) and Rybelsus (T2D, launched 2019), but orforglipron is expected to outperform these on-market semaglutide options for a number of reasons: superior HbA1c reduction and weight loss
In airplanes and EDF jets, sustained load matters even more, which makes continuous discharge logic usually more useful than burst claims
By facilitating the transport of fatty acids into the mitochondria, it helps the body utilize fat as a fuel source, making it ideal for those looking to improve endurance and promote weight loss
